norepinephrine. The structurally similar compound, tacrine, which is a known allosteric modulator of the muscarinic receptors, is also shown to be a modulator of the α 1 adrenergic receptors, which suggests a general lack of selectivity for allosteric binding sites across aminergic GPCRs. Conjugation of two 9-aminoacridine pharmacophores, using linkers of varying length, increases the potency and efficacy of the allosteric effects of this ligand, likely through optimisation of bitopic engagement of the allosteric and orthosteric binding sites of the receptor. Such a bivalent approach may provide a mechanism for fine tuning the efficacy of allosteric compounds in future drug design efforts.
Abstract
The α 1 adrenergic receptors are targets for a number of cardiovascular and CNS conditions, however current drugs for these receptors lack specificity to be of optimal clinical value. Allosteric modulators offer an alternative mechanism of action to traditional α 1 adrenergic ligands, yet there is little information describing this drug class at the α 1 adrenergic receptors. We have identified a series of 9-aminoacridine compounds that demonstrate allosteric modulation of the α 1A and α 1B adrenergic receptors. The 9-aminoacridines increase the rate of [ 3 H]prazosin dissociation from the α 1A and α 1B adrenergic receptors and non-competitively inhibit receptor activation by the endogenous agonist, norepinephrine. The structurally similar compound, tacrine, which is a known allosteric modulator of the muscarinic receptors, is also shown to be a modulator of the α 1 adrenergic receptors, which suggests a general lack of selectivity for allosteric binding sites across aminergic GPCRs. Conjugation of two 9-aminoacridine pharmacophores, using linkers of varying length, increases the potency and efficacy of the allosteric effects of this ligand, likely through optimisation of bitopic engagement of the allosteric and orthosteric binding sites of the receptor. Such a bivalent approach may provide a mechanism for fine tuning the efficacy of allosteric compounds in future drug design efforts.
Introduction
Allosteric modulators offer a number of potential advantages over traditional, orthosterically acting drugs including maintenance of spatio-temporal patterns of physiological signalling (Christopoulos, 2002) . These advantages are of particular value in the central nervous system (CNS) where perturbation of G protein-coupled receptor (GPCR) signalling, or direct and sustained stimulation/inhibition of receptors frequently leads to limiting side-effects (Conn et al., 2014) . Therefore, allosteric modulators of GPCRs are of growing interest as drugs to target validated, but otherwise intractable receptors, particularly in the CNS.
One of the main hurdles to the use of allosteric modulators remains their identification from drug screens. This, coupled with the general lack of structural information about allosteric pockets on GPCRs, means allosteric modulators remain relatively underrepresented as drugs for GPCRs. One of the few exceptions to this is the muscarinic acetylcholine receptor family, where crystal structures are publically available for 4 of the 5 subtypes (Kruse et al., 2012; Thal et al., 2016; Thorsen et al., 2014) , one of which has an allosteric modulator bound (Kruse et al., 2013) , and radiolabelled allosteric ligands are available (Schober et al., 2014; Tränkle et al., 2003) . These serve as excellent models for fundamental properties of allosteric modulators, but many other GPCR families still lack defined allosteric sites, or many examples of allosteric ligands.
One family of GPCRs with potential CNS, as well as peripheral applications are the subtype has been validated as a potential target to treat seizure disorders arising in the CNS (Hillman et al., 2009; Pizzanelli et al., 2009; Zuscik et al., 2001) , as well as for the treatment of heart failure (Du et al., 2006; Lin et al., 2001) . However a common hurdle for the This article has not been copyedited and formatted. The final version may differ from this version. successful targeting of this receptor family is subtype selectivity (Chen and Minneman, 2005) . Even clinically relevant drugs such as prazosin, silodosin and naftopidil possess less than 100-fold selectivity for their target receptor over other α 1 adrenergic receptor subtypes, as well as other biogenic amine receptors such as the 5-HT 1A serotonin receptor (GlaxoSmithKline, 2011; Shibata et al., 1995; Takei et al., 1999) . Subtype selectivity is desirable as the α 1A subtype which has the most therapeutic potential frequently exhibits opposing actions to the α 1B subtype (Hillman et al., 2009; Milano et al., 1994) .
Allosteric modulators have the potential to overcome many of these barriers, yet there are few examples of allosteric modulators for the α 1 adrenergic receptor family (Leppik et al., 2000; Pfaffendorf et al., 2000; Sharpe et al., 2003; Waugh et al., 1999) , and even less structural information regarding any allosteric site/s (Ragnarsson et al., 2015; Ragnarsson et al., 2013 ). Here we have employed an innovative approach to maximise the allosteric effect observable for a potential allosteric ligand. We have used a series of homobivalent derivatives of 9-aminoacridine with increasing linker lengths (Figure 1 ), which were previously identified as having unexpectedly high affinity for the α 1 adrenergic receptors with some tissue specific differences in binding affinity (Adams et al., 1986; Adams et al., 1985) . The three subtypes of the α 1 adrenergic receptors had not been described at that time, but the observed differences in affinity were attributed to different binding modes of the bis(9-aminoacridine)s depending on the length of the linker, and the potential existence of a second pocket, or cleft, on tissue specific receptors. We hypothesise that the observed differences in binding affinity are attributable to subtype selective binding of the bis-(9-aminoacridine)s, and that the postulated " cleft" constitutes an allosteric site on the α 1 adrenergic receptors. Additionally, we predicted that an optimally sized bivalent ligand will maximise occupancy of an allosteric site, increasing its observable effects.
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Transfection and membrane preparation
Cells were seeded at a density of 4.5 x 10 6 cells per 175 cm 2 flask and transfected 24 h later using 20 µg DNA per 175 cm 2 flask as per the DEAE dextran method of Lopata et al. (1984) . 48-72 h after transfection, cells were harvested by scraping into cold PBS and pelleted by centrifugation at 500 x g for 5 min at 4°C. The pellet was resuspended in cold HE buffer (20 mM HEPES, 10 mM EDTA, pH 7.4) using 10 mL of buffer for each 175 cm 2 plate scraped. Suspensions were homogenised on ice using an Ultra-Turax T125 homogeniser at 20,000 r.p.m. in three 10 s bursts. Lysate was centrifuged at 600 x g for 10 min at 4°C.
Supernatant was then centrifuged at 40 000 x g for 1 h at 4°C. The final pellet was resuspended in cold 20 mM HEPES (pH 7.4) + 10% glycerol (v/v) using 200 μ L per 175 cm 2 flask then homogenised on ice using an insulin syringe, aliquoted and stored at -80°C. Protein concentration was measured using Bradford reagent.
Transfection and IP Accumulation
Resuspended COS-1 cells were diluted to a concentration of 1 x 10 5 cells.mL -1 DMEM and transfected with 1 μ g construct and 2 μ L jetPEI transfection reagent per 1 x 10 5 cells as per the manufacturer's instructions. Cells were plated into 96 well plates (220 μ L per well) and left at room temperature for 1 h following transfection to minimise uneven plating in the outmost wells (Lundholt et al., 2003) , then transferred to a 37°C, 5% CO 2 incubator. 16-24 h post-transfection, receptor activation was determined using total soluble inositol phosphate (IP) production as previously described (Campbell et al., 2014) in the presence of 10 µM propranolol to inhibit any potential signalling from β adrenergic receptors.
Binding assays
All radioligand binding assays were performed at room temperature in duplicate. α 1 This article has not been copyedited and formatted. The final version may differ from this version. 
Data analysis
All binding data was analysed in GraphPad Prism 6 by non-linear regression using standard one-site curves for saturation and dissociation kinetics assays. Competition binding assays were fit by a variable-slope competition binding model (Cheng and Prusoff, 1973; Hill, 1910) . All values were compared by one-way ANOVA with Tukey post-test. IP accumulation data was analysed in GraphPad Prism 6 by non-linear regression using a variable slope, four-parameter fit. Inhibitor affinity was estimated by generating a double reciprocal plot of equi-effective concentrations of agonist in the absence and presence of inhibitor at a concentration that produces an approximate 50% decrease in the maximum signal (Ehlert, 1988; Kenakin, 1997) .
This article has not been copyedited and formatted. The final version may differ from this version. (Newman-Tancredi et al., 1998; Zhao et al., 1996) . 9-aminoacridine, the parent monomer of the bis(9-aminoacridine)s, has an affinity of 247 nM for the α 1A adrenergic receptor, is 10-fold selective over the α 1B adrenergic receptor (K i : 2.6 µM, P<0.01), 8-fold selective over the α 1D adrenergic receptor (K i : 1.9 µM, P<0.001), and greater than 400-fold selective over the 5-HT 1A receptor (K i : >100 µM) (Table 1, Figure 2 ).
To investigate whether the affinity of 9-aminoacridine is dependent upon it being fully aromatic, the affinity of its tetra-hydro derivative, tacrine, was also measured (Figure 1 ). Figure 2 ). Thus tacrine binding is consistently weaker than 9-aminoacridine at the α 1A and α 1B adrenergic receptors (P < 0.01), but it still maintains selectivity for α 1A over α 1B (P < 0.05).
In general, the bis(9-aminoacridine)s studied show low-to sub-micromolar affinity for This article has not been copyedited and formatted. The final version may differ from this version. Figure 2 ). At the α 1B and α 1D adrenergic receptors the bis(9-aminoacridine)s have similar or greater affinity than 9-aminoacridine for all linker lengths tested, their affinity-chain length relationship producing a shallow, concave profile with maximum affinity occurring around the C5, C6, and C7 homologues (Table 1, Figure 2 ). In contrast, at the α 1A adrenergic receptor this profile is more pronounced, particularly for bis(9-aminoacridine)s with linkers between 2 and 7 carbons (Table 1, Figure   2 ). Whereas the bis(9-aminoacridine)s display only 5-and 7-fold differences between the highest and lowest affinity compounds at the α 1B and α 1D adrenergic receptors, at the α 1A adrenergic receptor there is a 91-fold difference between the highest and lowest affinity compounds, C4 and C2 bis(9-aminoacridine), respectively. At the α 1A adrenergic receptor C2
has an affinity of 1.9 μ M, which is significantly lower than that of 9-aminoacridine (P < 0.01), while the affinity of C4, at 21 nM, is significantly higher than that of 9-aminoacridine as well as that of C2, C3 and all other bis(9-aminoacridine)s with linkers longer than 6 carbons (P < 0.05). The affinity of C4 bis(9-aminoacridine) at the α 1A adrenergic receptor is the highest observed for any of the bis(9-aminoacridine)s at all of the tested receptors ( Figure   2 ), the ligand being 10-fold selective over the α 1B subtype (P < 0.001), 30-fold selective over the α 1D adrenergic receptor (P < 0.001), and 145-fold selective over the 5-HT 1A receptor (P < 0.001). All bis(9-aminoacridine)s with a linker length of five carbons or fewer have significantly higher affinity for the three α 1 adrenergic receptor subtypes than the 5-HT 1A
receptor. Affinities of the shorter bis(9-aminoacridine)s, C2 and C3, as well as the monovalent 9-aminoacridines for the 5-HT 1A receptor are some of the lowest observed in the test set, resulting in substantial selectivity for the α 1 adrenergic receptor subtypes.
Close observation reveals that the slopes of the competitive binding curves for some of the bis(9-aminoacridine)s at the α 1 adrenergic receptors appear steeper than that generated by the competitive antagonist phentolamine ( Table 2 ). The Hill coefficients of phentolamine binding do not differ significantly from unity for any α 1 adrenergic receptor, nor for serotonin binding at the 5-HT 1A receptor (Table 2) . There is a similar finding for the monomers 9-aminoacridine and tacrine ( (Carruthers, 1994; Cavalli et al., 1997) , the modulatory effects of the bis(9-aminoacridine)s on prazosin dissociation rates from these two receptors were characterised.
In preliminary experiments to identify appropriate experimental conditions, we found that measurements in HEM buffer yielded a half-life of 14 min for the dissociation of negative allosteric modulation. However, dissociation from the α 1B adrenergic receptor in this buffer was slow with less than 50% dissociation observed after 2 hours (data not shown).
This difficulty was overcome by the use of TE buffer for this receptor, as described by Sato et al. (2012) , in which the half-life was 33 min. Accordingly, HEM buffer was used for kinetic experiments with the α 1A adrenergic receptor, and TE buffer for experiments with the α 1B adrenergic receptor.
Bis(9-aminoacridine)s increase the dissociation rate of [ 3 H]prazosin
The dissociation rate of [ 3 H]prazosin was measured in the absence and presence of the bis(9-aminoacridine)s, 9-aminoacridine, and tacrine at 100 μ M, this being the highest concentration possible, limited by bis(9-aminoacridine) solubility. At 100 µM, 9-aminoacridine causes a 3.2-fold increase in dissociation rate at the α 1A adrenergic receptor and a 5.5-fold increase in dissociation rate at the α 1B adrenergic receptor (Table 3) . Tacrine shows a similar, albeit less efficacious, profile resulting in a 2.1-fold increase in dissociation rate from the α 1A adrenergic receptor and a 4.2-fold increase from the α 1B adrenergic receptor (Table 3) . With the exception of C2 and C3, the bis(9-aminoacridine)s significantly increase the dissociation rate of [ 3 H]prazosin from the α 1A adrenergic receptor (P < 0.05) in a linkerlength dependent manner (r 2 =0.86, P<0.001) ( Table 3) . There is a similar finding for the α 1B adrenergic receptor where all the bis(9-aminoacridine)s increase the dissociation rate of Table 3 ).
The C2-to-C9 bis(9-aminoacridine)s all produce a greater proportional increase in dissociation rate at the α 1B adrenergic receptor (P < 0.01), while C12 gives the greatest observed effect at the α 1A adrenergic receptor (Table 3) . However, the use of different buffers in the dissociation kinetics assays for each of the subtypes makes it difficult to compare potency between the receptor subtypes as affinity and efficacy of allosteric ligands are known to change in different buffers (Ellis and Seidenberg, 2000; Schroter et al., 2000) .
This article has not been copyedited and formatted. The final version may differ from this version. To investigate whether the potency of the bis(9-aminoacridine)s to modulate the dissociation rate of [ 3 H]prazosin from the adrenergic receptors is correlated with their observed binding affinity, the α 1A -selective C4 bis(9-aminoacridine), the non-selective C9 bis(9-aminoacridine), as well as the monomer 9-aminoacridine were chosen for a more thorough characterisation. Tacrine was again included to investigate whether planarity of the molecule is a necessary feature for modulation. The increase in [ receptor, yet allosteric properties only emerge at a minimum concentration of 30 µM. C4 bis(9-aminoacridine) causes a maximum 3.5-fold increase in dissociation rate at the α 1A adrenergic receptor but does not cause an observable increase in rate at 10 μ M, well above its apparent affinity of 21 nM for this receptor. In contrast, it causes a maximum 9.0-fold increase in dissociation at the α 1B adrenergic receptor that appears to be close to saturating, producing an estimated EC 50(diss) of 22 µM (Figure 3 ), a concentration ~100-fold higher than its apparent affinity. C9 bis(9-aminoacridine) causes a 17.6-fold increase in dissociation rate from the α 1A adrenergic receptor at 100 μ M (P<0.001) and a 62.3-fold increase in dissociation rate from the α 1B adrenergic receptor (P<0.001). This produces EC 50(diss) estimates of 32 and 6 µM for the α 1A and α 1B adrenergic receptors, respectively (Figure 3 ). Despite C4 bis(9-aminoacridine) having higher affinity than C9 at the α 1A adrenergic receptor, this was not translated into increased modulation potency. C9 bis(9-aminoacridine) consistently causes greater increases in [ Table 4 ). 100 µM C9 also causes a small but significant increase in receptor signalling via the IP 3 pathway in the absence of norepinephrine (Table 4) . The IP accumulation data do not fit
well to an operational model of allosterism (Leach et al., 2007) , generating unrealistic or poor fit values e.g. R 2 < 0.5, β < 0, or α > 10 12 . This is possibly due to a bitopic, rather than purely allosteric binding mode of C9 bis(9-aminoacridine). Instead, the method of Ehlert (1988) In addition to competitive binding, the acridines also demonstrate allosteric effects at the α 1 adrenergic receptors, supporting the prediction that the 9-aminoacridines are able to interact with a second site. These allosteric effects occur at free ligand concentrations well above the apparent affinity of the 9-aminoacridines indicating a relatively low affinity interaction with the allosteric site. The lack of any observable binding cooperativity for the This article has not been copyedited and formatted. The final version may differ from this version. monovalent ligands is also consistent with a low-affinity, allosteric interaction; the orthosteric site would be saturated before any significant allosteric effect can be observed. Cooperative binding may only emerge for the bivalent ligands as a result of one acridine moiety being tethered to the higher-affinity orthosteric site, creating a high local concentration of ligand around the allosteric pocket and increasing the likelihood of an allosteric binding event. The
Hill slopes most different from 1 at the α 1 adrenergic receptors occur around the 9-carbon linker, suggesting that this length is optimal for promoting concomitant engagement of both the orthosteric and allosteric sites.
An interesting observation is that the potency and magnitude of the allosteric effect of the bis(9-aminoacridine)s correlates better with linker length than apparent affinity, viz, C4 bis(9-aminoacridine) is not the most potent modulator despite displaying the highest affinity.
This implies that the allosteric interactions are associated with a binding site that is distinct from the site that is imparting high-affinity binding interactions. For the α 1B subtype, the allosteric effect appears to peak at the 9-carbon length, further reinforcing this as the optimal linker length for bitopic binding at the α 1 adrenergic receptors. This supports our prediction that an optimally sized bivalent ligand will promote engagement of an allosteric site to exaggerate the allosteric effects of a ligand with otherwise poor efficacy or potency.
Interestingly, 9 carbons was also found to be the optimum length to promote bitopic engagement of the reciprocally bivalent compound, THRX-198321 a dual β 2 adrenergic receptor agonist and muscarinic receptor antagonist (Steinfeld et al., 2011) perhaps suggesting a conserved distance between orthosteric and allosteric pockets in the biogenic amine receptor family.
One caveat to our model of bitopic binding for the
is that it may require the existence of dimers, or higher order oligomers, of the α 1 adrenergic receptors.
A bitopic model best satisfies the observed pharmacology of the bis(9-aminoacridine)s, This article has not been copyedited and formatted. The final version may differ from this version. We have demonstrated that a single pharmacophore can have actions at two distinct receptor binding sites. One of the most significant implications of this observed pharmacology for the 9-aminoacridines is that the orthosteric and allosteric sites of the α 1 adrenergic receptors, and potentially many other GPCRs, share some degree of similarity. In addition, monovalent tacrine, tacrine dimers and methoctramine also show similar effects at muscarinic receptors, with mixed orthosteric-allosteric actions and the homobivalent ligands are also suggested to bind in a bitopic manner (Jakubik et al., 2014; Pearce and Potter, 1988; Tränkle et al., 2005) . This observation would be in line with current understanding of ligand binding mechanisms. Recent structural biology efforts to crystallise GPCRs have yielded a structure of the M 2 muscarinic receptor with a bound positive allosteric modulator, LY2119620 (Kruse et al., 2013) . This structure showed the allosteric modulator bound to an allosteric pocket comprised of residues from transmembrane (TM) helices TMV, TMVI, TMVII, and the second extracellular loop, which have previously been shown to constitute the primary allosteric site for the muscarinic receptors (Prilla et al., 2006; Valant et al., 2012) . dissociation rate also appears to be in the mid to high micromolar range.
"Pure" orthosteric and allosteric ligands may then simply be ligands with significant selectivity for one site over the other and the differences in 9-aminoacridine affinity between the two sites (~100-fold) is not substantial enough to give a single binding profile. It is possible that some effects of allosteric modulators may be attributable to interaction with the orthosteric site e.g. "allosteric agonists" may be allosteric ligands with additional, hitherto unappreciated weak orthosteric agonist activity. Such a multi-pocket mechanism of action has recently been described for some ligands of the FFA2 free fatty acid receptor (Grundmann et al.) . The two identified pockets are considerably more superficial on the receptor surface, are in closer proximity and have more similar affinities than is expected for the aminergic
receptors, but nonetheless demonstrate that a single ligand can have distinct actions at topographically distinct sites on a single receptor.
The observed effects of tacrine, as well as the other 9-aminoacridines, at the tacrine, an allosteric ligand of the muscarinic receptors (Pearce and Potter, 1988; Potter et al., 1989; Tränkle et al., 2005) , is also an allosteric ligand of the α 1 adrenergic receptors, in addition to its orthosteric activity at the two receptor families. There may therefore be conservation of allosteric sites in related receptor families, which would also explain why there appears to be a conserved distance between the orthosteric and allosteric sites in Structure of 9-aminoacridine, tacrine (tetrahydro-9-aminoacridine), and the general structure for bis(9-aminoacridine) in their protonated state. This article has not been copyedited and formatted. The final version may differ from this version. pEC 50 : negative log of the concentration required to cause 50% maximal norepinephrine mediated activation. Slope: slope factor of norepinephrine mediated receptor activation E max : % maximum norepinephrine response measured in the absence of C9 bis(9-aminoacridine). Basal: agonist independent receptor activity, expressed as % norepinephrine E max .
*, **, *** P < 0.05, 0.01, 0.001 compared to norepinephrine alone by one-way ANOVA with Tukey post-test.
